- Why Research
- Our Impact
- Get Involved
- About BCRF
- Research is the reason
- Contact Us
You are here
Charles Loprinzi, MD
Regis Professor of Breast Cancer Research
- Seeking to improve quality of life for breast cancer patients by reducing or avoiding treatment-related side effects.
- Studies are ongoing to reduce skin toxicity resulting from radiation therapy, nose symptoms related to paclitaxel chemotherapy and chemotherapy-related nerve damage.
- These efforts will provide evidence-based recommendations to reduce the side effects of cancer and cancer treatments.
While cancer therapies are effective at treating the cancer, they also have unwanted effects and toxicities. Patients being treated for breast cancer may experience a variety of side effects due to their therapy–some passing quickly, others lingering long after therapy ends, and still others that emerge many years later. Dr. Loprinzi is conducting a series of studies aimed at reducing the side effects of cancer treatments with the goal of improving quality of life during and after treatment.
Full Research Summary
Patients diagnosed with breast cancer can have multiple undesired symptoms related to receiving cancer therapy. A trial performed by Dr. Loprinzi’s research team has shown that cooling the hands and feet with ice is a promising new way of decreasing chemotherapy-associated nerve damage. Another trial supports the idea that a clinically available drug, oxybutynin, commonly used for patients with bladder control problems, decreases hot flashes associated with anti-estrogen therapy.
This year, the team is focusing on three areas. One is related to using a thin film to try to prevent the commonly observed, prominent skin toxicity that is associated with radiation treatment. Another addresses bothersome nose symptoms related to paclitaxel chemotherapy, to better define which drugs cause this problem and potential means of treating this problem. The last is to evaluate a drug called fingolimod as a means of preventing and/or treating chemotherapy-related nerve damage. This drug, which is clinically available to treat multiple sclerosis, appears promising in laboratory animal model studies to prevent and treat chemotherapy-associated nerve damage.
Dr. Loprinzi is currently the Regis Professor of Breast Cancer Research at the Mayo Clinic, Rochester, MN where he is an emeritus chair of the Division of Medical Oncology and an emeritus Vice-Chair of the Department of Oncology.
He has run an active cancer control program directed toward both cancer prevention efforts and symptom control efforts, which has led to the publication of over 300 articles and book chapters, with over 100 publications in the Journal of Clinical Oncology.
Dr. Loprinzi served as the founding editor for the Art of Oncology section of the Journal of Clinical Oncology from 2000 through 2010. In addition, he edited two anthologies of articles from the Art of Oncology series that are available via the Kindle electronic book format.
His work has lead to him receiving two awards from the Susan G. Komen Foundation: the Komen Foundation Brinker award in 2002 and the 2005 Komen Foundation Professor of Survivorship. In 2005, he was awarded the 2006 Clinical Research Award by the Association of Community Cancer Centers (ACCC). In 2006, he was awarded the North American Menopausal Society (NAMS) Vasomotor Symptoms Research Award.
BCRF Investigator Since
The ANN INC. Award (a division of ascena retail group inc.)